US HIFU, LLC (US HIFU) is engaged in the distribution of medical equipments. It markets image-guided acoustic ablation devices developed using ultrasound energy for the detection of cancer and soft tissue diseases. The company distributes Sonablate 500 which is developed for prostate disease therapy using High Intensity Focused Ultrasound (HIFU). Its uses intersecting, precision-focused ultrasound waves and raises the temperature of the target tissue to more than 80 to 90 degrees Celsius for destroying the tissue. Sonablate 500 currently undergoing phase III clinical trial in US. It distributes across Europe, Canada, China, Australia, Japan, Costa Rica, South Africa and the Caribbean. US HIFU is headquartered at Charlotte in North Carolina, the US.
Recently, the company entered into a partnership with Riverside Research Institute (RRI) for the development and testing of an ultrasonic method of prostate imaging and treatment.